A 78-year-old woman with brain metastases

Clinical Chemistry

Volumn 61, Issue 4, 2015, Pages 584-586

  Tafe, Laura J ^a,b   Tsongalis, Gregory J ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; AGED; ARTICLE; BRAIN FOURTH VENTRICLE; BRAIN METASTASIS; CASE REPORT; CEREBELLUM TUMOR; COMPUTER ASSISTED TOMOGRAPHY; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEADACHE; HUMAN; MODERATELY DIFFERENTIATED ADENOCARCINOMA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; RIGHT HEMISPHERE; THORACOLUMBAR SPINE; BRAIN NEOPLASMS; ENDOMETRIAL NEOPLASMS; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; RADIOGRAPHY; SECONDARY;

ADENOCARCINOMA; AGED; BRAIN NEOPLASMS; ENDOMETRIAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84925832559     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.229864     Document Type: Article

References (10)

1. Lindeman NI, Cagle PT, Beasley M.B., Chitale DA, Dacic S, Giaccone G, et al. College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection oflung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013; 15:415-53.
2. Sasaki H, Endo K, Takada M., Kawahara M, Kitahara N, Tanaka H., et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007; 58:324-8.
3. Massarelli E, Johnson FM, Erickson H.S., Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 2013; 80:235-41.
4. Arcila ME, Nafa K, Chaft J.E., Rekhtman N., Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clini-copathologic characteristics. Mol Cancer Ther 2013; 12:220-9.
5. Oxnard GR, Lo PC, Nishino M, Dahlberg S.E., Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 2013; 8:179-84.
6. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, et al. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol 21(SUPPL. 4):S490-6.
7. Yasuda H, Park E, Yun C.H., Sng NJ, Lucena-Araujo AR, Yeo WL, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013; 5:216ra177.
8. Chen X, Zhu Q, Zhu L., Pei D, Liu Y, Yin Y., et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer 2013; 81:155-61.
9. Yang JCH, Sequist LV, Geater S.L., Tsai CM, Mok T Schuler MH, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer. Oral session presented at: the World Congress on Lung Cancer; 2013 Oct 27-31; Sydney, Australia.
10. Yasuda H, Kobayashi S, Costa DB. EGFR exon20 insertion mutationsinnon-small-cell lungcancer: preclinical data and clinical implications. Lancet Oncol 2012; 13:e23-31.